Literature DB >> 15879028

Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland.

Mika Paldanius1, Aini Bloigu, Marianne Alho, Maija Leinonen, Pekka Saikku.   

Abstract

The rates of Chlamydia pneumoniae seroconversions suggesting acute primary infections or reinfections and the prevalences of antibodies were followed up among healthy laboratory workers. Annual serum samples were collected from 47 persons in Helsinki from 1958 to 1990 and from 40 persons in Oulu from 1994 to 1999. C. pneumoniae species-specific immunoglobulin G (IgG), IgA, and IgM antibodies were measured by microimmunofluorescence (MIF) in 407 sera from Helsinki. The 185 sera collected in Oulu were tested both by MIF and by commercial enzyme immunoassay (EIA). During the follow-up periods of 31 years in Helsinki and 6 years in Oulu, seroconversions were demonstrated by MIF in 45% and 15% of the study groups, respectively. In Helsinki 9% of the persons seroconverted twice during the follow-up period. By MIF, the total incidence rate per 100 person-years at risk was 6.9 in Helsinki and 4.9 in Oulu, and annual incidence rates varied from 0 to 15.4. By EIA, annual incidence rates in Oulu varied from 0 to 10.8. The seroconversions by MIF were usually not confirmed by EIA and vice versa. Prevalence and persistence rates, respectively, of IgA antibodies were higher in EIA (62% and 26%) than in MIF (26% and 17%), whereas the figures for IgG were quite similar. The prevalence of IgG and IgA antibodies was higher in older persons than in younger ones. The presence of antibodies did not offer protection from reinfection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879028      PMCID: PMC1112086          DOI: 10.1128/CDLI.12.5.654-659.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  48 in total

1.  Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis.

Authors:  H S Markus; M Sitzer; D Carrington; M A Mendall; H Steinmetz
Journal:  Circulation       Date:  1999-08-24       Impact factor: 29.690

2.  The microimmunofluorescence test for Chlamydia pneumoniae infection: technique and interpretation.

Authors:  S p Wang
Journal:  J Infect Dis       Date:  2000-06       Impact factor: 5.226

Review 3.  Background and current knowledge of Chlamydia pneumoniae and atherosclerosis.

Authors:  J T Grayston
Journal:  J Infect Dis       Date:  2000-06       Impact factor: 5.226

Review 4.  Epidemiologic association of Chlamydia pneumoniae and atherosclerosis: the initial serologic observation and more.

Authors:  P Saikku
Journal:  J Infect Dis       Date:  2000-06       Impact factor: 5.226

5.  Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma.

Authors:  D L Hahn; T Anttila; P Saikku
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

6.  Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis.

Authors:  J Danesh; P Whincup; M Walker; L Lennon; A Thomson; P Appleby; Y Wong; M Bernardes-Silva; M Ward
Journal:  BMJ       Date:  2000-07-22

7.  Evidence of 2 waves of Chlamydia pneumoniae infection in Gävle, Sweden, 1990-96.

Authors:  H Gnarpe; J Gnarpe; A Lundbäck
Journal:  Scand J Infect Dis       Date:  1999

8.  Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae immunoglobulin G and A antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays.

Authors:  T Tuuminen; S Varjo; H Ingman; T Weber; J Oksi; M Viljanen
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

9.  Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice.

Authors:  E Blessing; T M Lin; L A Campbell; M E Rosenfeld; D Lloyd; C Kuo
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

10.  Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease.

Authors:  L Von Hertzen; H Alakärppä; R Koskinen; K Liippo; H M Surcel; M Leinonen; P Saikku
Journal:  Epidemiol Infect       Date:  1997-04       Impact factor: 2.451

View more
  7 in total

1.  Persistent Chlamydia Pneumoniae serology is related to decline in lung function in women but not in men. Effect of persistent Chlamydia pneumoniae infection on lung function.

Authors:  Thorarinn Gislason; Vilmundur Guðdnason; Bryndis Benediktsdottir; Isleifur Olafsson; Thor Aspelund; Bjarni Thjodleifsson; Christer Janson
Journal:  BMC Pulm Med       Date:  2010-08-25       Impact factor: 3.317

2.  Reliable and Sensitive Nested PCR for the Detection of Chlamydia in Sputum.

Authors:  Martina Smolejová; Iveta Cihová; Pavol Sulo
Journal:  Microorganisms       Date:  2021-04-27

Review 3.  Laboratory diagnosis of persistent human chlamydial infection.

Authors:  Mirja Puolakkainen
Journal:  Front Cell Infect Microbiol       Date:  2013-12-17       Impact factor: 5.293

4.  The association of mannose binding lectin genotype and immune response to Chlamydia pneumoniae: The Strong Heart Study.

Authors:  Laine Monsey; Lyle G Best; Jianhui Zhu; Susan DeCroo; Matthew Z Anderson
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

5.  Higher incidence of persistent chronic infection of Chlamydia pneumoniae among coronary artery disease patients in India is a cause of concern.

Authors:  Hem C Jha; Harsh Vardhan; Rishein Gupta; Rakesh Varma; Jagdish Prasad; Aruna Mittal
Journal:  BMC Infect Dis       Date:  2007-05-30       Impact factor: 3.090

6.  Evaluation and optimization of a commercial enzyme linked immunosorbent assay for detection of Chlamydophila pneumoniae IgA antibodies.

Authors:  Olfa Frikha-Gargouri; Radhouane Gdoura; Abir Znazen; Nozha Ben Arab; Jalel Gargouri; Mounir Ben Jemaa; Adnene Hammami
Journal:  BMC Infect Dis       Date:  2008-07-26       Impact factor: 3.090

7.  Protein microarray-mediated detection of antienterovirus antibodies in serum.

Authors:  Aiying Zhang; Bingshui Xiu; Heqiu Zhang; Ning Li
Journal:  J Int Med Res       Date:  2016-02-01       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.